How a bacteria exploits cell processes to survive and spread.
Anaplasma phagocytophilum exploitation of regulated exocytosis.
['FUNDING_FELLOWSHIP'] · VIRGINIA COMMONWEALTH UNIVERSITY · NIH-11118658
This study is looking at how a germ called Anaplasma phagocytophilum tricks our immune cells to survive longer, and by understanding this, we hope to find new ways to help people fight off infections caused by it.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIRGINIA COMMONWEALTH UNIVERSITY (nih funded) |
| Locations | 1 site (RICHMOND, UNITED STATES) |
| Trial ID | NIH-11118658 on ClinicalTrials.gov |
What this research studies
This research investigates how the bacterium Anaplasma phagocytophilum manipulates the process of regulated exocytosis in human neutrophils, which are key immune cells. By understanding the mechanisms that allow this pathogen to evade destruction and promote its own survival, the research aims to uncover potential targets for new treatments. The study will involve examining the interactions between the bacteria and host cells, focusing on calcium signaling and other molecular pathways that are altered during infection. Patients may benefit from insights gained into how to better combat infections caused by this pathogen.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with human granulocytic anaplasmosis or those at risk of infection from tick bites.
Not a fit: Patients with other types of infections or those not affected by tick-borne diseases may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating infections caused by Anaplasma phagocytophilum.
How similar studies have performed: While the specific mechanisms of Anaplasma phagocytophilum exploitation of exocytosis are less studied, similar approaches have shown promise in understanding other bacterial infections.
Where this research is happening
RICHMOND, UNITED STATES
- VIRGINIA COMMONWEALTH UNIVERSITY — RICHMOND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHIARELLI, TRAVIS JOSEPH — VIRGINIA COMMONWEALTH UNIVERSITY
- Study coordinator: CHIARELLI, TRAVIS JOSEPH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.